Literature DB >> 21518930

RUNX1 regulates corepressor interactions of PU.1.

Zhenbo Hu1, Xiaorong Gu, Kristine Baraoidan, Vinzon Ibanez, Arun Sharma, ShriHari Kadkol, Reinhold Munker, Steven Ackerman, Giuseppina Nucifora, Yogen Saunthararajah.   

Abstract

The transcription factor (TF) RUNX1 cooperates with lineage-specifying TFs (eg, PU.1/SPI1) to activate myeloid differentiation genes, such as macrophage and granulocyte macrophage colony-stimulating factor receptors (MCSFR and GMCSFR). Disruption of cooperative gene activation could contribute to aberrant repression of differentiation genes and leukemogenesis initiated by mutations and translocations of RUNX1. To investigate the mechanisms underlying cooperative gene activation, the effects of Runx1 deficiency were examined in an in vitro model of Pu.1-driven macrophage differentiation and in primary cells. Runx1 deficiency decreased Pu.1-mediated activation of Mcsfr and Gmcsfr, accompanied by decreased histone acetylation at the Mcsfr and Gmcsfr promoters, and increased endogenous corepressor (Eto2, Sin3A, and Hdac2) coimmunoprecipitation with Pu.1. In cotransfection experiments, corepressors were excluded from a multiprotein complex containing full-length RUNX1 and PU.1. However, corepressors interacted with PU.1 if wild-type RUNX1 was replaced with truncated variants associated with leukemia. Histone deacetylase (HDAC) enzyme activity is a major component of corepressor function. HDAC inhibition using suberoylanilide hydroxamic acid or MS-275 significantly increased MCSFR and GMCSFR expression in leukemia cell lines that express PU.1 and mutated or translocated RUNX1. RUNX1 deficiency is associated with persistent corepressor interaction with PU.1. Thus, inhibiting HDAC can partly compensate for the functional consequences of RUNX1 deficiency.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21518930      PMCID: PMC3123020          DOI: 10.1182/blood-2010-10-312512

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Cooperative and antagonistic interplay between PU.1 and GATA-2 in the specification of myeloid cell fates.

Authors:  Jonathan C Walsh; Rodney P DeKoter; Hyun Jun Lee; Erica D Smith; David W Lancki; Michael F Gurish; Daniel S Friend; Richard L Stevens; John Anastasi; Harinder Singh
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

2.  ETO sequence may be dispensable in some AML1-ETO leukemias.

Authors:  Adriana Lasa; Josep F Nomdedeu; Maria J Carnicer; Andreu Llorente; Jorge Sierra
Journal:  Blood       Date:  2002-12-01       Impact factor: 22.113

3.  Protein expression and constitutive phosphorylation of hematopoietic transcription factors PU.1 and C/EBP beta in acute myeloid leukemia blasts.

Authors:  H Iida; M Towatari; M Iida; M Tanimoto; Y Kodera; A M Ford; H Saito
Journal:  Int J Hematol       Date:  2000-02       Impact factor: 2.490

4.  C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies.

Authors:  Vijaya Vegesna; Seisho Takeuchi; Wolf-K Hofmann; Takayuki Ikezoe; Sigal Tavor; Utz Krug; Anthony C Fermin; Anthony Heaney; Carl W Miller; H Phillip Koeffler
Journal:  Leuk Res       Date:  2002-05       Impact factor: 3.156

5.  In vivo complex formation of PU.1 with HDAC1 associated with PU.1-mediated transcriptional repression.

Authors:  F Kihara-Negishi; H Yamamoto; M Suzuki; T Yamada; T Sakurai; T Tamura; T Oikawa
Journal:  Oncogene       Date:  2001-09-20       Impact factor: 9.867

6.  Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)?

Authors:  Charlotte Lamandin; Christophe Sagot; Christophe Roumier; Pascale Lepelley; Stéphane De Botton; Alain Cosson; Pierre Fenaux; Claude Preudhomme
Journal:  Blood       Date:  2002-12-15       Impact factor: 22.113

7.  RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation.

Authors:  Kamaleldin E Elagib; Frederick K Racke; Michael Mogass; Rina Khetawat; Lorrie L Delehanty; Adam N Goldfarb
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

8.  Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A.

Authors:  Mohammed Milhem; Nadim Mahmud; Donald Lavelle; Hiroto Araki; Joseph DeSimone; Yogen Saunthararajah; Ronald Hoffman
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

9.  Heterozygous PU.1 mutations are associated with acute myeloid leukemia.

Authors:  Beatrice U Mueller; Thomas Pabst; Motomi Osato; Norio Asou; Lisa M Johansen; Mark D Minden; Gerhard Behre; Wolfgang Hiddemann; Yoshiaki Ito; Daniel G Tenen
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

Review 10.  Runx transcription factors and the developmental balance between cell proliferation and differentiation.

Authors:  James A Coffman
Journal:  Cell Biol Int       Date:  2003       Impact factor: 3.612

View more
  29 in total

Review 1.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors:  Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

Review 2.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

Review 3.  Fetal Hemoglobin Induction by Epigenetic Drugs.

Authors:  Donald Lavelle; James Douglas Engel; Yogen Saunthararajah
Journal:  Semin Hematol       Date:  2018-04-22       Impact factor: 3.851

4.  Poly(C)-Binding Protein Pcbp2 Enables Differentiation of Definitive Erythropoiesis by Directing Functional Splicing of the Runx1 Transcript.

Authors:  Louis R Ghanem; Andrew Kromer; Ian M Silverman; Xinjun Ji; Matthew Gazzara; Nhu Nguyen; Gabrielle Aguilar; Massimo Martinelli; Yoseph Barash; Stephen A Liebhaber
Journal:  Mol Cell Biol       Date:  2018-07-30       Impact factor: 4.272

5.  A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.

Authors:  Boet van Riel; Tibor Pakozdi; Rutger Brouwer; Rui Monteiro; Kapil Tuladhar; Vedran Franke; Jan Christian Bryne; Ruud Jorna; Erik-Jan Rijkers; Wilfred van Ijcken; Charlotte Andrieu-Soler; Jeroen Demmers; Roger Patient; Eric Soler; Boris Lenhard; Frank Grosveld
Journal:  Mol Cell Biol       Date:  2012-07-16       Impact factor: 4.272

6.  Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.

Authors:  Yogen Saunthararajah; Mikkael Sekeres; Anjali Advani; Reda Mahfouz; Lisa Durkin; Tomas Radivoyevitch; Ricki Englehaupt; Joy Juersivich; Kathleen Cooper; Holleh Husseinzadeh; Bartlomiej Przychodzen; Matthew Rump; Sean Hobson; Marc Earl; Ronald Sobecks; Robert Dean; Frederic Reu; Ramon Tiu; Betty Hamilton; Edward Copelan; Alan Lichtin; Eric Hsi; Matt Kalaycio; Jaroslaw Maciejewski
Journal:  J Clin Invest       Date:  2015-01-26       Impact factor: 14.808

Review 7.  The RUNX1-PU.1 axis in the control of hematopoiesis.

Authors:  Maria Rosaria Imperato; Pierre Cauchy; Nadine Obier; Constanze Bonifer
Journal:  Int J Hematol       Date:  2015-03-08       Impact factor: 2.490

8.  Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates.

Authors:  Xiaorong Gu; Quteba Ebrahem; Reda Z Mahfouz; Metis Hasipek; Francis Enane; Tomas Radivoyevitch; Nicolas Rapin; Bartlomiej Przychodzen; Zhenbo Hu; Ramesh Balusu; Claudiu V Cotta; David Wald; Christian Argueta; Yosef Landesman; Maria Paola Martelli; Brunangelo Falini; Hetty Carraway; Bo T Porse; Jaroslaw Maciejewski; Babal K Jha; Yogen Saunthararajah
Journal:  J Clin Invest       Date:  2018-07-17       Impact factor: 14.808

9.  Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy.

Authors:  Xiaorong Gu; Zhenbo Hu; Quteba Ebrahem; John S Crabb; Reda Z Mahfouz; Tomas Radivoyevitch; John W Crabb; Yogen Saunthararajah
Journal:  J Biol Chem       Date:  2014-04-02       Impact factor: 5.157

10.  Epigenetic modifier directed therapeutics to unleash healthy genes in unhealthy cells.

Authors:  Babal K Jha; Yogen Saunthararajah
Journal:  Semin Hematol       Date:  2020-12-14       Impact factor: 3.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.